NasdaqGS:JAZZPharmaceuticals
How Investors Are Reacting To Jazz (JAZZ) Zepzelca Failing Phase 3 LAGOON Survival Endpoint
Jazz Pharmaceuticals recently reported that the Phase 3 LAGOON trial of Zepzelca in relapsed second-line metastatic small cell lung cancer failed to improve overall survival versus physician’s choice of chemotherapy, although safety remained consistent with prior data.
An important nuance is that these LAGOON results do not affect Zepzelca’s existing full U.S. approval in the first-line maintenance setting, leaving its current commercial use in that indication unchanged while raising...